ECM
EUCRU

Endurant Capital Management’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

Endurant Capital Management’s Portfolio EUCRU Stock Details EUCRU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-195,000
Closed -$2.08M – 75
2020
Q4 		$2.08M Buy
+195,000
New +$1.98M 0.75% 42

Other funds holding EUCRU

Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Magnetar Financial
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Endurant Capital Management's EUCRU Position: Q1 2021 in Review

Endurant Capital Management sold out of Eucrates Biomedical Acquisition Corp. Unit (EUCRU) in Q1 2021, closing a stake of 195,000 shares — an estimated $2.08M sold.

Endurant Capital Management first reported a position in EUCRU in Q4 2020 and held it in 1 quarter. The position peaked at $2.08M in Q4 2020. 23 funds tracked by Wall St. Rank hold EUCRU as of Q1 2021.

  • Endurant Capital Management reported no remaining Eucrates Biomedical Acquisition Corp. Unit position as of Q1 2021 after selling out during the quarter.
  • Endurant Capital Management sold 195,000 Eucrates Biomedical Acquisition Corp. Unit shares in Q1 2021, an estimated $2.08M.
  • Endurant Capital Management first reported a position in Eucrates Biomedical Acquisition Corp. Unit in Q4 2020 and held it in 1 quarter.
  • Endurant Capital Management's Eucrates Biomedical Acquisition Corp. Unit position peaked at $2.08M in Q4 2020.
  • 23 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Unit as of Q1 2021.

Based on Endurant Capital Management's 13F filing for Q1 2021, filed 17 May 2021.